Immunogenicity and safety of a fully liquid DTaP-IPV-HB-PRP∼T hexavalent vaccine compared with the standard of care in infants in the Republic of Korea

A3L31 Study Group

Research output: Contribution to journalArticlepeer-review

10 Scopus citations
Original languageEnglish
Pages (from-to)4022-4028
Number of pages7
Issue number32
StatePublished - 13 Jul 2017

Bibliographical note

Funding Information:
This study was supported by Sanofi Pasteur, Lyon, France.

Funding Information:
The authors acknowledge the study personnel for the conduct of the study and also all enrolled infants and parents/legal guardian(s) for their participation. This manuscript was prepared with the assistance of a professional medical writer, Dr Andrew Lane (Lane Medical Writing), in accordance with the European Medical Writers Association guidelines and Good Publication Practice. This study was funded by Sanofi Pasteur.

Cite this